Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ultra-rapid selection of the N74D capsid inhibitor resistance mutation after 3 weeks on lenacapavir.

The Journal of antimicrobial chemotherapy - 1 Jul 2024

Wirden Marc, Pouderoux Cecile, Peytavin Gilles, Abdi Basma, Fayçal Antoine, Palich Romain, Valantin Marc Antoine, Seang Sophie, Katlama Christine, Calvez Vincent, Pourcher Valerie, Marcelin Anne-Geneviève

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Capsid Proteins
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Quinolones

Share to SARS-CoV-2

Share to Selection, Genetic

Source

Identifiers

PMID: 38629483
DOI: 10.1093/jac/dkae115

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ultra-rapid selection of the N74D capsid inhibitor resistance mutation after 3 weeks on lenacapavir.PMID 38629483Read ↗

Recurrent and novel evolutionary pathways drive in vitro HIV-1 lenacapavir resistance with diverse phenotypic consequences.Semantic proximity Read ↗

Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy With Lenacapavir-containing RegimenSemantic proximity Read ↗

Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects.Semantic proximity Read ↗

Pharmacokinetics, pharmacodynamics, efficacy and drug resistance selection of injectable long-acting lenacapavir pre-exposure prophylaxis (PrEP) against HIVSemantic proximity Read ↗

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.Semantic proximity Read ↗

COVID drug drives viral mutations - and now some want to halt its use.Semantic proximity Read ↗

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsSemantic proximity Read ↗

Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir.Semantic proximity Read ↗

Structural and Mechanistic Bases for Resistance of the M66I Capsid Variant to LenacapavirSemantic proximity Read ↗

Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavirSemantic proximity Read ↗

Characterization of human immunodeficiency virus (HIV-1) envelope glycoprotein variants selected for resistance to a CD4-mimetic compoundSemantic proximity Read ↗

HIV-1 Resistance to the Capsid-Targeting Inhibitor PF74 Results in Altered Dependence on Host Factors Required for Virus Nuclear EntrySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.